They encapsulated plasminogen activator within nanobubbles and conjugated these nanobubbles with recombinant antibodies targeting β2GPI, achieving highly specific and efficient thrombolytic therapy in APS-prone thrombosis sites (157). This evidence concerns the gene APOH and autoimmune polyendocrinopathy.